• 180+

    The UK’s most active investor in UK university spin-outs

  • £500M

    Over £500m raised; invested into over 180 companies

  • £150M

    Cash returned to investors via exits

  • £1.1Bn

    Part of FTSE 250 sector specialist group with £1.1bn net assets

About Parkwalk

Parkwalk is one of the UK’s leading growth fund managers backing world-changing technologies emerging out of UK universities and research institutions with the aim of delivering world-class returns.

Performance

We back high potential, hard science technology companies that aim to shape the future by commercialising innovation in sectors of strategic importance to UK Plc, such as AI, big data, life science, materials, cleantech, future of mobility, medtech and quantum computing.

Learn More

Parkwalk Open Funds

Parkwalk offer early-stage investment funds, investing in high-growth, knowledge intensive companies spun out of the UK’s world-leading universities and providing tax benefits under the Enterprise Investment Scheme.

Opportunities EIS Fund

Our evergreen EIS Fund, investing in EIS-qualifying hard science and deep tech companies spun out of universities across the UK.
Learn More

University of Cambridge Enterprise Fund X

Our UCEF X invests in high-growth, IP-rich technologies founded at the University of Cambridge.
Learn More

Meet the Parkwalk team

Combining our diverse range of skills and experience with integrity and transparency the Parkwalk team has an outstanding track record for supporting high-growth innovation that delivers returns.

Susie Harris
Gordon Lawson
Alastair Kilgour
Meet the team

Empowering Innovation

Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.

Carbometrics

Carbometrics is a specialist supramolecular chemistry company. Carbometrics’ core technology is a synthetic molecule that was intricately designed to bind to glucose – A Glucose Binding Molecule (GBM) – which is being used to develop a new glucose sensor chemistry that can help patients manage diabetes, via Continuous Glucose Monitors (CGM).

Congenica

Congenica has translated research from the Sanger Institute, based on ground breaking research from the Deciphering Developmental Disorders Study, which collected genetic data from 40,000+ people at 24 NHS labs into a clinical genomics analytical platform, called Sapienta. Congenica’s software will enable the accurate, rapid and scalable clinical interpretation of genetic and clinical data,

PharmEnable

PharmEnable is a drug discovery company using advanced medicinal chemistry and AI approaches to develop highly complex and specific drug candidate molecules

View Portfolio